Eurasian Patent Organization: These 30 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Eurasian Patent Organization
Generic Entry Dates in Other Countries
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Summary: Eurasian Patent Organization: These 30 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
| Tradename | Ingredient | Estimated Entry Opportunity Date |
|---|---|---|
| QVAR REDIHALER | beclomethasone dipropionate | 2027-04-11 |
| FARYDAK | panobinostat lactate | 2026-06-12 |
| OLYSIO | simeprevir sodium | 2026-07-28 |
| >Tradename | >Ingredient | >Estimated Entry Opportunity Date |
Details: Eurasian Patent Organization: These 30 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch?
Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 11, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 16,831
This drug has two hundred and seventy-eight patent family members in twenty-seven countries. There has been litigation on patents covering QVAR REDIHALER
See drug price trends for QVAR REDIHALER.
The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.
When can FARYDAK (panobinostat lactate) generic drug versions launch?
Generic name: panobinostat lactate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 12, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,984
FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.
This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK
See drug price trends for FARYDAK.
The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 15,131
OLYSIO is a drug marketed by Janssen Prods. There are eight patents protecting this drug.
This drug has sixty-four patent family members in forty-one countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,229
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,428
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 28,259
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 35,999
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 18, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,545
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 18, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 24,152
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can INTRAROSA (prasterone) generic drug versions launch?
Generic name: prasterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 10, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,683
This drug has fifty-nine patent family members in thirty-two countries.
See drug price trends for INTRAROSA.
The generic ingredient in INTRAROSA is prasterone. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the prasterone profile page.
When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?
Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 24, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,203
SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.
See drug price trends for SIGNIFOR LAR.
The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,806
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,229
This drug has four hundred and twenty-five patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,428
This drug has four hundred and twenty-five patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 28,259
This drug has four hundred and twenty-five patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 35,999
This drug has four hundred and twenty-five patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can JARDIANCE (empagliflozin) generic drug versions launch?
Generic name: empagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,608
This drug has four hundred and twenty-eight patent family members in forty-six countries. There has been litigation on patents covering JARDIANCE
See drug price trends for JARDIANCE.
The generic ingredient in JARDIANCE is empagliflozin. There are twenty-two drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the empagliflozin profile page.
When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch?
Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 01, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 15,180
This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI
See drug price trends for OSENI.
The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 01, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,883
PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 03, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 34,294
PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,229
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,428
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 28,259
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 35,999
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 05, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,091
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
This drug has ninety-seven patent family members in thirty-nine countries.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.
When can TRADJENTA (linagliptin) generic drug versions launch?
Generic name: linagliptin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 30, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 29,890
This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA
See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.
When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?
Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 16, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 15,287
This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX
See drug price trends for TRINTELLIX.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.
When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?
Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 16, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,058
This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX
See drug price trends for TRINTELLIX.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.
When can XADAGO (safinamide mesylate) generic drug versions launch?
Generic name: safinamide mesylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,123
This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO
See drug price trends for XADAGO.
The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.
When can XADAGO (safinamide mesylate) generic drug versions launch?
Generic name: safinamide mesylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 25,326
This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO
See drug price trends for XADAGO.
The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.
When can ZEMDRI (plazomicin sulfate) generic drug versions launch?
Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 21, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,824
ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug.
This drug has twenty-eight patent family members in twenty-one countries. There has been litigation on patents covering ZEMDRI
See drug price trends for ZEMDRI.
The generic ingredient in ZEMDRI is plazomicin sulfate. Three suppliers are listed for this generic product. Additional details are available on the plazomicin sulfate profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 20, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,707
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.
This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.
When can TWIRLA (ethinyl estradiol; levonorgestrel) generic drug versions launch?
Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,208
This drug has nineteen patent family members in twelve countries.
See drug price trends for TWIRLA.
The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this API. Twenty-three suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch?
Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 16,782
TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.
This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO
See drug price trends for TEPMETKO.
The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.
When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch?
Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,281
TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.
This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO
See drug price trends for TEPMETKO.
The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,900,066
This drug has four hundred and twenty-five patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,171,333
This drug has four hundred and twenty-five patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,490,902
This drug has four hundred and twenty-five patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,791,254
This drug has four hundred and twenty-five patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 202,091,391
This drug has four hundred and twenty-five patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,900,066
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,171,333
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,490,902
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,791,254
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 202,091,391
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,800,881
ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can FARYDAK (panobinostat lactate) generic drug versions launch?
Generic name: panobinostat lactate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 12, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,802,383
FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.
This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK
See drug price trends for FARYDAK.
The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.
When can XADAGO (safinamide mesylate) generic drug versions launch?
Generic name: safinamide mesylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,028
This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO
See drug price trends for XADAGO.
The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.
When can XADAGO (safinamide mesylate) generic drug versions launch?
Generic name: safinamide mesylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,101,308
This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO
See drug price trends for XADAGO.
The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 20, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,868
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.
This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.
When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch?
Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 11, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,907
This drug has two hundred and seventy-eight patent family members in twenty-seven countries. There has been litigation on patents covering QVAR REDIHALER
See drug price trends for QVAR REDIHALER.
The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,000,032
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.
When can TWIRLA (ethinyl estradiol; levonorgestrel) generic drug versions launch?
Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,123
This drug has nineteen patent family members in twelve countries.
See drug price trends for TWIRLA.
The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this API. Twenty-three suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 18, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,870,063
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 18, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,201,452
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can ZEMDRI (plazomicin sulfate) generic drug versions launch?
Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 21, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,597
ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug.
This drug has twenty-eight patent family members in twenty-one countries. There has been litigation on patents covering ZEMDRI
See drug price trends for ZEMDRI.
The generic ingredient in ZEMDRI is plazomicin sulfate. Three suppliers are listed for this generic product. Additional details are available on the plazomicin sulfate profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,900,066
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,171,333
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,490,902
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,791,254
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 202,091,391
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can JARDIANCE (empagliflozin) generic drug versions launch?
Generic name: empagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,000,321
This drug has four hundred and twenty-eight patent family members in forty-six countries. There has been litigation on patents covering JARDIANCE
See drug price trends for JARDIANCE.
The generic ingredient in JARDIANCE is empagliflozin. There are twenty-two drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the empagliflozin profile page.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 05, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,532
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
This drug has ninety-seven patent family members in thirty-nine countries.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.
When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch?
Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,000,093
TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.
This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO
See drug price trends for TEPMETKO.
The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.
When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch?
Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,000,094
TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.
This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO
See drug price trends for TEPMETKO.
The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.
When can INTRAROSA (prasterone) generic drug versions launch?
Generic name: prasterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 10, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,000,312
This drug has fifty-nine patent family members in thirty-two countries.
See drug price trends for INTRAROSA.
The generic ingredient in INTRAROSA is prasterone. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the prasterone profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,013
JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?
Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 16, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,018
This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX
See drug price trends for TRINTELLIX.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.
When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?
Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 16, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,870
This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX
See drug price trends for TRINTELLIX.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 03, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,971,018
PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 01, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,400,387
PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 03, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,991,590
PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.
When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch?
Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,164
This drug has ninety patent family members in forty-one countries. There has been litigation on patents covering KAZANO
See drug price trends for KAZANO.
The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. There are ten drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.
When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?
Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 24, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,901,523
SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.
See drug price trends for SIGNIFOR LAR.
The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.
When can TRELSTAR (triptorelin pamoate) generic drug versions launch?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 06, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,971,132
TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
See drug price trends for TRELSTAR.
The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can ZTALMY (ganaxolone) generic drug versions launch?
Generic name: ganaxolone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,290
ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug.
This drug has forty-nine patent family members in sixteen countries. There has been litigation on patents covering ZTALMY
See drug price trends for ZTALMY.
The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this generic product. Additional details are available on the ganaxolone profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,150
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
This drug has seventy patent family members in twenty-nine countries.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,575
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
This drug has seventy patent family members in twenty-nine countries.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.
When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 06, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,971,132
TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can JESDUVROQ (daprodustat) generic drug versions launch?
Generic name: daprodustat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 23, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,220
JESDUVROQ is a drug marketed by Glaxosmithkline. There are six patents protecting this drug.
This drug has forty-four patent family members in thirty-one countries.
See drug price trends for JESDUVROQ.
The generic ingredient in JESDUVROQ is daprodustat. One supplier is listed for this generic product. Additional details are available on the daprodustat profile page.
When can JESDUVROQ (daprodustat) generic drug versions launch?
Generic name: daprodustat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 23, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,050
JESDUVROQ is a drug marketed by Glaxosmithkline. There are six patents protecting this drug.
This drug has forty-four patent family members in thirty-one countries.
See drug price trends for JESDUVROQ.
The generic ingredient in JESDUVROQ is daprodustat. One supplier is listed for this generic product. Additional details are available on the daprodustat profile page.
When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch?
Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 11, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 15,756
This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA
See drug price trends for DAKLINZA.
The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.
When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch?
Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 11, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,900,298